Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
$0.00
$0.00
$0.00
$0.01
N/A-0.241,662 shsN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$0.25
-16.5%
$0.35
$0.25
$2.08
$1.84M0.1728,664 shs619,988 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
0.00%0.00%+81.43%+15.45%+20.95%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-16.50%-15.95%-26.69%-27.71%-78.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/AN/AN/AN/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/AN/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.14M0.37N/AN/A$3.63 per share0.07

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/AN/A0.00N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.95MN/A0.00N/A-115.76%-54.31%-46.23%5/20/2024 (Estimated)

Latest CNCT, INM, and DODS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/13/2024Q2 2024
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$0.19-$0.19-$0.19N/A$1.24 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
7.03
6.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%

Insider Ownership

CompanyInsider Ownership
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
China Teletech Holding, Inc. stock logo
CNCT
China Teletech
3N/AN/ANot Optionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
136.06 million5.97 millionNot Optionable

CNCT, INM, and DODS Headlines

SourceHeadline
Inmed’s INM-089 shows functional and pathological improvements in in vivo AMD modelsInmed’s INM-089 shows functional and pathological improvements in in vivo AMD models
bioworld.com - April 18 at 3:58 PM
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimers Expert, to the Companys Scientific Advisory BoardInMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
newsfilecorp.com - April 18 at 8:00 AM
InMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMDInMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD
theglobeandmail.com - April 17 at 12:42 PM
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular DegenerationInMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
newsfilecorp.com - April 16 at 8:00 AM
InMeds INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimers Disease StudiesInMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
newsfilecorp.com - April 4 at 8:00 AM
InMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day ExtensionInMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension
theglobeandmail.com - March 23 at 9:38 PM
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid ComplianceInMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
newsfilecorp.com - March 20 at 8:30 AM
Reshaping The Global Epidermolysis Bullosa Therapeutics Market With Latest Trends And Market OpportunitiesReshaping The Global Epidermolysis Bullosa Therapeutics Market With Latest Trends And Market Opportunities
opprairie.com - February 20 at 8:01 AM
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateInMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
newsfilecorp.com - February 13 at 5:41 PM
InMed Pharmaceuticals Welcomes New CFO Neeta JagpalInMed Pharmaceuticals Welcomes New CFO Neeta Jagpal
markets.businessinsider.com - February 10 at 9:11 AM
InMed Pharmaceuticals Announces New CFO AppointmentInMed Pharmaceuticals Announces New CFO Appointment
msn.com - February 10 at 9:11 AM
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial OfficerInMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
finance.yahoo.com - February 9 at 9:43 AM
InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet NeedInMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need
benzinga.com - January 25 at 9:27 PM
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ETInMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
finance.yahoo.com - January 18 at 6:37 PM
InMed Pharmaceuticals: InMed Announces Results of 2023 Annual General MeetingInMed Pharmaceuticals: InMed Announces Results of 2023 Annual General Meeting
finanznachrichten.de - December 20 at 7:49 AM
InMed Announces Results of 2023 Annual General MeetingInMed Announces Results of 2023 Annual General Meeting
finance.yahoo.com - December 19 at 8:08 PM
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateInMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
finance.yahoo.com - November 14 at 8:42 AM
InMed Pharmaceuticals files to sell 12.57M shares for holdersInMed Pharmaceuticals files to sell 12.57M shares for holders
msn.com - November 8 at 6:33 PM
InMed Pharmaceuticals Inc INMInMed Pharmaceuticals Inc INM
morningstar.com - November 8 at 1:32 AM
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
finance.yahoo.com - November 2 at 9:37 AM
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesInMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - October 27 at 12:17 AM
Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?
investorplace.com - October 25 at 11:02 AM
InMed Pharmaceuticals to raise $5.2M via private placementInMed Pharmaceuticals to raise $5.2M via private placement
msn.com - October 24 at 6:06 PM
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq RulesInMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
finance.yahoo.com - October 24 at 6:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

China Teletech logo

China Teletech

OTCMKTS:CNCT
China Teletech Holding, Inc. does not have significant operations. Previously, it was engaged in the design, development, manufacture, and distribution of lithium-ion polymer batteries, micro batteries, and smart cards. The company was founded in 2006 and is based in Shenzhen, China.
InMed Pharmaceuticals logo

InMed Pharmaceuticals

NASDAQ:INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.